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ABSTRACT
Aim: The diagnosis and treatment of acromegaly, a rare and possibly curable disease, has undergone a paradigm shift in 
the past few decades. Our aim was to study the changing trends in clinical presentation, management and outcome of the 
disease in the last fifteen years.
Methodology: 271 consecutive patients with acromegaly treated at the Departments of Endocrinology and Neurosurgery, 
PGIMER, Chandigarh, between 2000 and 2014, were included in the study. Clinical and hormonal profiles, comorbidities, 
treatment modalities, outcome and mortality data were evaluated. The cure rate was assessed according to the present 
consensus criteria.
Results: The gender distribution was equal with the mean age (±SD) of 37.1 ± 12.3 years at diagnosis. The average 
lag period to diagnosis was 4.7 ± 4.2 years. The most common presenting manifestations were acral enlargement and 
headache followed by visual deficits. The overall mortality rate was 5%, with the perioperative mortality being 1.5%. The 
most prevalent comorbidities in our series were hypertension (17.7%), diabetes mellitus (16.2%), arthropathy (11.8%) and 
obstructive sleep apnea (10.3%). Overall, 2 patients in our series suffered from extra-pituitary neoplasms and 12 patients 
had apoplexy as the presenting manifestation. As per the present consensus criteria, the cure rate in our series was 28.5%. 
The cure rate was only 7.9% when many surgeons were operating. It increased to 25.5% when surgeries were being 
performed by one surgeon exclusively; and, when a sub-specialty clinic exclusively for pituitary diseases was set up, the 
cure rates improved upto 56%.
Conclusion: Acromegaly has wide-ranging manifestations from acral enlargement to altered sensorium; incidental diagnosis 
was not prevalent in our series. Majority of the cases were due to the presence of a pituitary macroadenoma. Better cure 
rates can be achieved only when a dedicated group of multi-disciplinary team is involved.
Key words: Acromegaly; clinical features; outcome; somatotropinoma
Introduction
Acromegaly, an uncommon disease, is caused by chronic 
hypersecretion of growth hormone (GH), usually by a 
pituitary adenoma. The annual incidence of acromegaly is 
3 per million and the prevalence is 40 per million.[1] The 
disease has seen a paradigm shift in the diagnosis and 
treatment in the past few decades. We evaluated patients 
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with acromegaly treated at PGIMER, Chandigarh, India over 
the past 15 years, with the aim to study their different 
clinical presentations, associated comorbidities and their 
outcome following treatment.
Patients and Methods
This series includes 271 acromegalic patients treated between 
January 2000 and December 2014 at the Departments of 
Endocrinology and Neurosurgery, PGIMER, Chandigarh. The 
inclusion criteria was the presence of nadir plasma GH level 
greater than (>) 1 ng/ml on oral glucose tolerance test (OGTT); 
and/or, IGF‑1 levels above the upper limit of age‑matched 
range.[2] In the presence of concomitant diabetes mellitus, the 
diagnosis was made if any two out of the following criteria was 
met:	The	nadir	GH	levels	greater	than	or	equal	to	(≥)	5	ng/ml	
and IGF‑1 levels above the age matched range; or, the nadir GH 
levels > 0.4 ng/ml on OGTT performed after 2 weeks of glycemic 
control; or, a raised insulin‑like growth factor‑binding protein 3 
(IGFBP‑3) with the presence of clinical features of acromegaly and 
an adenoma on imaging.[3] At the time of inclusion, complete 
clinical details including the anthropometry were recorded 
for every patient. In addition to the routine preoperative 
biochemical investigations, the hormone profile including 
thyroid function tests (TFTs), luteinizing hormone (LH), follicle 
stimulating hormone (FSH) and prolactin (PRL) were measured by 
immunoradiometric assay on gamma counter (Perkin Elmer), while 
testosterone (T)/estradiol (E2) and cortisol (F) were measured 
using radioimmunoassay on a Rack beta counter (Wallace) until 
2008, and using electrochemiluminiscence on a COBAS 6000 
machine (Roche, Hitachi) after that period. GH was measured 
by immunoradiometric assay on gamma counter (Perkin Elmer) 
until 2006, by electrochemiluminescence (IMMULITE, Siemens, 
Germany) until 2011, and finally on COBAS 6000 (Roche Hitachi) 
for the duration 2012‑2014. IGF‑1 was measured from 2000 to 
2006 by enzyme immunoassay (DRG, Germany) kits and by 
chemiluminescence (JSD) for the period between 2007‑2014. 
The WHO standard 98/574 was used for GH assay and 02/254 
for IGF‑1. HbA1c was measured by high performance liquid 
chromatography (BioRad variant II). Genetic analysis for aryl 
hydrocarbon receptor‑interacting protein (AIP), multiple 
endocrine neoplasia (MEN)‑1 and CDK1B was randomly 
done in 45 patients by Multiplex Ligation‑dependent Probe 
Amplification (MLPA) using MRC‑Holland kit P244‑C1 (MK).
The record keeping and audit of cure was done by the 
endocrinologists independent of the neurosurgeons ensuring 
the process of an external audit.
OGTT (using 75 g anhydrous glucose) was performed for all 
patients and random GH values were measured pre‑operatively, 
in the immediate post‑operative period, at 6 hours post‑surgery, 
on the post‑operative day 1 to 5, and 6 weeks later. IGF‑1 was 
measured pre‑operatively and at 12 weeks post‑operatively for 
all patients in the last 8 years. Gadolinium enhanced cranial 
MRI focusing on the sella turcica with MR angiography of the 
circle of Willis was done as a routine departmental protocol. 
This is because the incidence of aneurysms is higher in these 
patients compared to the general population. Imaging was 
repeated during follow‑up to look for any residual tumor. 
Optical colonoscopy was performed for all patients until 2004, 
following which it was replaced by a multidetector CT (MDCT) 
colonoscopy.[4] Multiple neurosurgeons (n = 5) operated 
upon these patients till 2005. However thereafter, only a single 
dedicated pituitary surgeon (KKM) performed most (55%) of the 
surgeries. All biopsy specimens were sent for histopathology and 
immunostaining (after 2006), using antibodies against anterior 
pituitary hormones (LH, FSH, GH, PRL, ACTH, TSH). The criteria 
for cure was the random GH less than (<) 1 ng/ml or nadir GH 
during OGTT being less than (<) 0.4 ng/ml; and, the IGF‑1 levels 
within the normal range for age.
Statistics
The groups were compared using Student T test or Mann‑Whitney 
U test depending on their distribution. Multivariate analysis was 
used to predict factors affecting cure. The data was analyzed on 
SPSS software version 15 (Chicago, IL). The data was expressed 
as mean ± standard deviation, unless specified and a P value 
of < 0.05 was considered as significant.
Results
The ser ies  inc luded 134 male and 137 female 
patients, with the mean age at presentation being 
37 ± 12.5 years (range 4 – 73 years) [Figure 1]. The 
average lag period (from the onset of symptoms to diagnosis) 
was 56.3 ± 50.2 months (4.7 years) and the average body 
mass index (BMI) was 26.32 kg/m2. The mean height of the 
whole group was 167.2 cm and in the adolescent patients, it 
was 176.6 ± 13.6 cm (the average Indian standard height 
being 157.5 cm).
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Figure 1: Age wise distribution of patients 
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Aetiology
Majority of the cases were due to pituitary adenomas 
with two cases being due to ectopic GH and growth 
hormone‑releasing hormone (GHRH) secretion.[5,6] Out of the 
271 patients, 18 (6.6%) had a microadenoma, 26 (9.6%) had a 
mesoadenoma (intrasellar microadenoma) while the rest (83%) 
harbored a pituitary macroadenoma (including 44 (19.5%) 
patients	with	a	giant	adenoma	(≥4	cms	in	any	diameter).	One	
patient had an adenoma in an ectopic location (a pharyngeal 
pituitary adenoma). One patient had a choriostoma and another 
had a gangliocytoma accompanying the pituitary adenoma.[7] 
Seventy one (26.2%) adenomas had a suprasellar, 25 (9.2%) had 
a parasellar and 9 (3.3%) patients had an infrasellar extension. 
McCune‑Albright syndrome was the cause of acromegaly in 
8 patients and all of them had underlying fibrous dysplasia.[8] 
The Knosp grading was available for the last 100 patients 
[grade 0 – 20%, grade 1 – 20%, grade 2 – 20%, grade 3 – 15% 
and grade 4 – 25%][9] [Table 1].
Familial Acromegaly and Other Syndromes
In our series, 5 families (13 members, 4.5%) were having 
familial acromegaly with at least 2 affected members in 
each family [Figure 2]. Genetic analysis was performed in 
45 patients randomly. Two patients from one family were 
found to be positive for the aryl hydrocarbon receptor 
interacting protein (AIP) mutation and another member 
from the same family was an unaffected carrier. One young 
boy (aged 3 years) was positive for germline AIP mutation, 
and one of his sisters and father were silent carriers. Two 
of our patients had genetically proven multiple endocrine 
neoplasia (MEN‑1) syndrome. Both of them subsequently 
presented with a primary hyperparathyroidism.
Clinical Features
Our patients had a broad spectrum of presenting manifestations, 
ranging from acral enlargement, headache to lower 
gastrointestinal bleed and even diabetes mellitus. Overall, 
the 3 most common presentations were acral enlargement 
followed by headache and visual deficits. In the females, 
the third most common presentation was amenorrhea. All 
the clinical features have been listed in Table 2 while the 
malignancies/tumors observed are listed in Table 3. In all 
except one patient, malignancy was diagnosed synchronously 
with acromegaly, while it was metachronous in a patient 
with carcinoma of the ovary. As previously mentioned, the 
prevalence of colonic polyps was not increased.[10]
Acrogigantism was present in 45 (16.2%) patients 
(height >97th percentile for age). As stated in our previous 
series, these patients had higher GH levels and excepting for one 
patient, all other had a macroadenoma.[11] Two of these patients 
belonged to the same family (first cousins) and were diagnosed 
as cases of Familial Isolated Pituitary Adenoma (FIPA).
Unusual Presentations
A few patients presented with some unusual features like 
tonsillomegaly; seizures and auditory hallucinations (due 
to the tumor extension into the temporal lobe); and, 
hypotension and bleeding per rectum due to multiple 
colonic polyps. One patient presented with epistaxis due to 
apoplexy in the pituitary macroadenoma with an infrasellar 
extension.
Pre-treatment Hormonal Profile
Complete anterior pituitary hormone profile was available 
for 215 patients. The most common abnormality was 
cortisol deficiency followed by hypogonadism [Table 4]. 
Preoperatively,  the average nadir  GH level  was 
51.5 ng/ml (2.5‑1250 ng/ml) and only 10 (3.7%) patients 
had GH levels in the safe range (<2.5 ng/ml). Paradoxically, 
7 patients had raised GH levels but normal IGF‑1 levels 
matched for age. 183 (85.1%) patients had one or more 
anterior pituitary hormone deficiencies, with 106 patients 
Table 1: Different types of adenomas in our series
Adenoma size Age <30 years 
(n=78) (%)
Age >30 years 
(n=191) (%)
P value
Microadenoma 1 (1.3) 17 (8.9) 0.03
Mesoadenoma 6 (7.7) 20 (10.5) 0.47
Macroadenoma 71 (91) 154 (80.6) 0.01
Giant adenoma 17 (21.8) 27 (14.1) 0.14
Figure 2: Sagittal section of CT scan of head showing McCune – Albright 
syndrome as the cause of acromegaly. Gamma knife was given as primary 
therapy
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having one, 49 having two, and the remaining 28 having 
three hormone deficiencies.
Treatment Modalities Used
Majority of the patients underwent transsphenoidal surgery, 
performed by multiple pituitary surgeons till 2006 and 
after that mostly by a single surgeon (KKM). Five patients 
underwent surgery twice; four had a residual tumor, while 
one patient had a recurrent adenoma. Subfrontal approach 
was used for 14 invasive adenomas with suprasellar and 
parasellar extensions. Only 1 patient received gamma knife 
radiosurgery as a primary therapy [Table 5]. At follow‑up, 
15 patients received radiotherapy, 16 patients underwent 
gamma knife radiosurgery and 20 were on monthly octreotide 
depot preparation. Besides these, another 20 patients were 
prescribed cabergoline in the follow‑up period.
Post-treatment Hormone Profile
146 patients with a complete postoperative anterior 
pituitary hormone profile were included for analysis. In the 
Table 2: Clinical features at presentation in our series
Presenting manifestation Total cases 
(N=271)
Percent Age <30 years 
(n=78) (%)
Age >30 years 
(n=193) (%)
P value
Acral enlargement 241 88.9 70 (29) 171 (71) 0.78
Headache 133 49.1 42 (31.6) 91 (68.4) 0.32
Visual deficit 74 27.3 24 (32.4) 50 (67.6) 0.43
Hypertension 48 17.7 1 (2.1%) 47 (97.9) <0.001
Diabetes mellitus 44 16.23 8 (18.2%) 36 (81.8%) 0.06
Amenorrhea 54 19.93 20 (37) 34 (67) 0.02
Facial coarsening 37 13.65 9 (24.3) 28 (75.7) 0.5
Loss of libido/Erectile dysfunction 32 11.8 6 (18.8) 26 (81.2) 0.14
Goitre 18 6.64 5 (27.8) 13 (72.2) 0.92
Galactorrhea 16 5.9 7 (43.8) 9 (56.2) 0.23
Apoplexy 13 4.8 1 (7.7) 12 (92.3) 0.12
Altered sensorium 7 2.58 1 (14.3) 6 (85.7) 0.68
Diabetic ketoacidosis 6 2.2 0 6 (100) 0.19
Diplopia 2 0.74 2 (100) 0 0.08
Incidental 2 0.74 2 (100) 0 0.08
Respiratory manifestations
Sleep apnea 28 10.3 8 20
Nasal polyps 2 0.74 2 0
Cutaneous manifestations
Acanthosis nigricans 24 8.9 8 16
Skin tags 27 9.9 7 20
Hirsutism 9 3.3 4 5
Seborrhea 31 11.4 10 21
Cutis verticis gyrata (bull dog scalp) 2 0.74 0 2
Granulomatous cheilitis 1 0.37 0 1
Musculoskeletal manifestations
Back ache 7 2.6 2 5
Arthralgia 32 11.8 11 21
Crippling proximal myopathy 5 1.8 2 3
Quadriparesis 1 0.37 1 0
Paraparesis 2 0.74 1 1
Poliomyelitis (Figure 3) 2 0.74 2 0
Carpel tunnel syndrome 6 2.2 0 6
Fibrous dysplasia (Figure 4) 8 2.9 5 3
Mimicking motor neuron disease 1 0.37 0 1
Renal stone disease 8 2.9 6 2
Cardiovascular dysfunction
Cardiac dysfunction 10$ 3.6 3 7
Valvular lesions 5 1.8 3 2
Coronary artery disease 1 0.37 0 1
$Of these, the initial 4 were operated without optimization of cardiac function and all of them died. The rest were optimized with octreotide for at least 6 months
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Table 3: Different neoplasms present in acromegalic patients in 
our series
Neoplasms No. of subjects
Colon cancer 4
Meningioma 2
Breast cancer 2
Ovarian cancer 1
Papillary thyroid carcinoma 1
Chronic myeloid leukemia (BCR‑Abl positive) 1
Pleomorphic adenoma of parotid gland 1
Table 4: Pre‑treatment hormonal profile
Hormonal parameter Total cases (n=215) Percentage
Hypocortisolism 100 46.5
Hypogonadism 75 34.9
Hypothyroidism 49 22.8
Hyperprolactinemia 61 28.4
Table 6: Post‑treatment hormonal profile
Hormone parameter Total cases (%) 
(N=146)
New cases 
(%)*
Recovered 
(%)**
Hypocortisolism 81 (55.5) 26 (32) 17 (17)
Hypogonadism 56 (38.4) 11 (19.6) 13 (17.3)
Hypothyroidism 50 (34.2) 30 (60) 12 (24.5)
Hyperprolactinemia 11 (7.5) 2 (18.2) 27 (44.3)
*Percentage of new cases has been calculated by using the total cases of individual 
hormone parameters in the post‑treatment period as denominator. **Percentage has 
been calculated for recovered cases using the total cases of individual hormone 
parameters in the pre‑treatment period as denominator
Table 5: Treatment modalities used in our series
Type of surgery done Total cases 
(N=252)
Percentage
Transsphenoidal 233 92.5
Subfrontal approach 16 6.4
Primary gamma knife 1 0.4
Primary external beam radiotherapy 2 0.8
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
MICROADENOMA MACROADENOMA
UNCURED
CURED
Figure 3: Cure rate in microadenomas versus macroadenomas
Figure 4: Pedigree of a family with familial acromegaly
post‑treatment period, 129 (88.4%) patients had one or more 
hormonal deficiency, while 14 (5.2%) patients became GH 
deficient [Table 6].
Complications
The commonest complication in the postoperative period 
was CSF rhinorrhea followed by permanent diabetes 
insipidus [Table 7]. The complication rate for patients with 
a microadenoma was 35% while the same for those with 
a macroadenoma was 53.2%. Two patients suffered from 
sphenoditis, while one patient had a massive pulmonary 
thromboembolism that led to her demise. Fourteen (5.2%) 
patients had a classical triphasic response and 4 patients 
undergoing radiotherapy, developed radiation induced brain 
disorders in the form of encephalomalacia.[12]
Immunohistochemistry
Immunohistochemistry was available for 100 patients. Fifty 
biopsies were positive only for GH, 34 were positive for 
both GH and prolactin, 2 were positive only for prolactin, 
one biopsy was positive for ACTH and GH, while 13 were 
negative for all hormones. 7% of our patients had bone, dural 
or mucosal invasion.
Outcome
One hundered and seventy two patients were included 
for analysis as they had at least 6 months of follow‑up. 
Only 49 (28.5%) subjects were cured. Out of 123 uncured 
patients, 22 had elevated random GH values with 
normal IGF‑1 matched for age, while 6 had elevated 
IGF‑1 rather than GH levels. Overall, 6 patients had a 
physiological cure, defined as intact pituitary hormones 
with random GH <1 ng/ml and IGF‑1 levels normal for 
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age. The cure rate for microadenomas was 38.8% while 
that for macroadenomas was 18.6%. On multivariate 
analysis (n = 100), the cure was not influenced by pre 
treatment GH, IGF‑1, Knosp grading and/or dural invasion, 
GH positivity alone or GH + prolactin positivity. It was 
rather dependent on the adequacy of surgery.
Mortality
Fourteen (5.2%) patients died due to different causes [Table 8], 
the commonest being cardiovascular dysfunction. Out of the 
4 (1.5%) patients who died in the peri‑operative period, two 
patients had congestive cardiac failure, one patient developed 
fatal pulmonary thromboembolism and another patient died 
due to massive pneumocephalus following an inadvertent 
opening of the lumbar drain.
Discussion
This is a large series evaluating the clinical presentations 
and outcome of acromegalic patients from the Indian 
subcontinent. Our patients presented at a younger age and 
the lag period prior to the treatment was less as compared 
to other series emanating from this area. Moreover, 
patients with macroadenomas far outnumbered those with 
microadenomas and GH levels were very high. The mortality 
was 4.8% and only 28.5% patients were cured.
In the series by Nabarro, 18% patients had a microadenoma 
and 82% harbored a macroadenoma.[13] In our series, 6.6% 
had a microadenoma, 9.6% had a mesoadenoma, while 83% 
harbored a pituitary macroadenoma. Similar findings were 
seen in previous registries from Spain and Belgium where 73% 
and 79% patients harbored a macroadenoma, respectively.[14,15]
Patients with acromegaly may have a wide spectrum of 
presenting manifestations. In our series, the most common 
presenting manifestations were acral enlargement, headache 
and visual deficits. Although a previous review article 
mentions the incidence of apoplexy in pituitary adenomas 
ranging from 1% to 26%, the incidence of apoplexy in patients 
with acromegaly was 3.5% in the study by Nabarro and 4.8% 
in our series.[16,13] The prevalence of pigmented skin tags was 
45% while that of acanthosis nigricans was 9% to 29% in their 
study, both being higher than our figures.[17] The prevalence 
of secondary amenorrhea and loss of libido in males was less 
in our study when compared to the the study by Nabarro.[13]
Arthropathy, hypertension and diabetes mellitus were the 
three most common comorbidities [Table 9]. The prevalence 
of hypertension in acromegaly is variable, ranging from 18% to 
60%.[18] The prevalence of hypertension was 17% in our study, 
which was less as compared to the overall prevalence of 29.8% in 
the Indian population. It was, however, higher than the previous 
report of 14.5% from our institute.[19,20] Both genders were equally 
affected. This lesser prevalence of hypertension as compared to 
the overall prevalence in the Indian population could be due to 
abundance of younger patients in our series [Table 10].
The second most common comorbidity in our series was 
diabetes mellitus (16.23%). However, the incidence was less 
as compared to previous reports of 52.5% in a series from 
Russia and of 22.3% in the French registry. It was, however, 
comparable to Nabarro’s series.[21,22,13] The lower prevalence 
of diabetes mellitus was probably due to a younger age at 
presentation, a shorter lag period in the detection of the 
disease, and the inclusion of lesser number of patients having 
a family history of diabetes.
Arthropathy was less than the previously mentioned figure 
of 60% to 70%; again, perhaps due to the younger age 
at presentation and a shorter lag period in our series.[23] 
Obstructive sleep apnea was less as compared to the previous 
literature where, the prevalence ranged from 19% to 79%, 
with a rising trend seen from 1980s to 1990s due to the 
increased use of polysomnography for diagnosis of the 
syndrome.[24] Cardiac dysfunction affected 3.7% patients, 
Table 8: Causes of mortality in our series
Cause of mortality No. of subjects 
(n=14)
Congestive cardiac failure 4
Pulmonary thromboembolism 1
Inadvertent opening of lumbar drain with massive 
pneumocephalus
1
Apoplexy with congestive cardiac failure 1
Refractory septic shock with diabetic ketoacidosis 
and seizures
1
Massive hematuria due to vesicle calculus 1
Colon carcinoma 1
Fulminant hepatic failure (Hepatitis B positive) 1
Sudden respiratory arrest and quadriplegia due to 
coexisting atlanto‑axial dislocation
1
Carcinoma ovary with omental metastases, 
intestinal obstruction
1
Pulmonary tuberculosis 1
Table 7: Postoperative complications in our series
Complication Total cases Percentage
CSF rhinorrhea 52 19.2
Diabetes Insipidus (permanent) 19 7
Diabetes Insipidus (transient) 41 15.2
Meningitis 4 1.5
VIth nerve palsy 2 0.75
Cavernous carotid artery injury 2 0.75
CSF overdrainage 1 0.37
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which is comparable to 3.5% in Nabarro’s series.[13] Six patients 
also had an accompanying renal stone disease, in compliance 
with the available literature that points towards an increased 
incidence of micronephrolithiasis in acromegalics with a 
significant correlation with the disease duration.[25]
The notion of increased risk of malignancy in acromegalic 
patients, compared to the general population, is still 
controversial. There have been reports of development 
of colorectal carcinoma, breast cancer, prostatic cancer, 
thyroid cancer, and even hematological malignancies in 
acromegalics.[16,26] The most common neoplasm in our series 
was colorectal carcinoma having an incidence similar to that 
found in other large series; interestingly, majority of the 
neoplasms in our series were synchronous with the diagnosis 
of acromegaly. This could be due to GH – IGF‑1 axis acting 
as a promoter of these malignancies in patients having an 
underlying genetic predisposition.
Eighty five percent patients had one or more anterior pituitary 
hormone deficiencies, as compared to 39.7% from the Belgian 
acromegaly registry and 25.7% from the Spanish acromegaly 
registry.[14,15] This figure increased to 88.4% in the post‑treatment 
period which was again higher than the previous studies.[27] In 
another series from Germany, 48.7% patients had one or more 
hormonal deficiency after 3 months of surgery.[28] During 
follow‑up, 5.2% patients became GH deficient, which was less 
as compared to a previous report ( 9%).[29]
Except for a few selected cases where other approaches 
were used, 92.5% of our patients underwent transsphenoidal 
surgery. The post‑operative complication rate was higher in 
overall patients and in patients with a macroadenomas, as 
compared to the previous reports of 2% and 9.3%.[28,30]
The most important aspect in the management of acromegaly 
in past few years has been the revision of the criteria for 
endocrinological cure. A consensus statement released earlier 
this year recommends morning fasting GH and IGF‑1 levels in 
the normal range as the aim of medical treatment.[31,32] Before 
2006, using GH cut‑off of 2.5 ng/ml by immunoradiometric 
assay, the cure rate was 26.6%, while subsequently, using a 
criteria of 1 ng/ml by chemiluminescence gave a cure rate of 
28.8%. The overall cure rate in our series was 28.5%, which was 
low as compared to the previous reports that ranged from 57.3% 
to 64% when surgeries were performed by a single dedicated 
pituitary surgeon.[26,28] When multiple surgeons operated on 
these patients, the cure rate was 7.9%; while, the cure rate 
was 25.5% for the surgeries performed by a single dedicated 
pituitary surgeon (KKM) [Table 9]. Moreover, the cure rate 
increased dramatically after the first 100 surgeries done by one 
of the authors (KKM). If the last 75 patients operated after the 
setting up of the pituitary clinic are considered, the cure rate 
was 56%. meaning that a multi‑disciplinary team may provide 
much better results. It is also possible that the superior results 
could have been due to the progressively increasing experience 
of the single neurosurgeon operating on these cases. The low 
cure rate might also be explained by the lower cut‑off values 
Table 9: Cure rate for single versus multiple pituitary surgeons
Surgeon 2000 to 2004 2004 to 2009 2010 to 2014 Total Since advent of 
pituitary clinic
surgery cured (%) surgery cured (%) surgery cured (%) surgery cured (%) surgery cured (%)
Single dedicated surgeon 8 1 (12.5) 48 11 (22.9) 124 34 (27.4) 180 46 (25.5) 75 42 (56)
Others 11 1 (9) 24 2 (8.3) 3 0 (0) 38 3 (7.9) nil nil
Table 10: Comparison between different acromegaly series
Characterstic Present 
series
Nabarro’s 
series , 1987[13]
Spanish 
registry, 2004[15]
French 
registry, 2011[22]
Belgian 
registry, 2007[14]
Ezzat S 
et al, 1994[1]
Sarkar S 
et al., 2014[41]
Place India London Spain France Belgium Multicentre India
Authors Dutta et al Nabarro JD Mestrón A et al Fieffe S et al. Bex M et al Ezzat S et al Sarkar S et al
No. of patients 271 256 1219 519 418 500 113
Male: female ratio 0.98 1.1 0.65 0.83 1.03 0.88 0.98
Mean age at diagnosis (years) 37.1 33.8 45 46.1 44 40 38.1
Diabetes mellitus prevalence 16.23% 18.8% 37.6% 22.35 25.3% 30% 29.2%
Hypertension prevalence 17.7% 30.5% 39.1% 33.7% 39.4% 51% 37.1%
Arthropathy prevalence 14.4% 18% 19.6% 55.7% 46.7% 45% ‑#
Neoplasm prevalence 4% 10.2% 7.5% ‑# 10.5% ‑# ‑#
Individual hormone parameters Evaluated Evaluated ‑# ‑# ‑# ‑# Evaluated 
Cure rate 28.5% 21.9% 40.3% ‑# 27% ‑# 31.9%
Mortality 5.2% 18.4% 4.6% ‑# 6.7% ‑# ‑#
#Not known or not mentioned in the study
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follow up MRI picture or the pattern of immunostaining, as 
stated previously by Minniti et al. [Figures 6 and 7].[33‑35]
Literature mentions an increased risk of early death in 
acromegalics, ranging from 34.6% to 39.4%, with major 
causes being cardiovascular, cerebrovascular and respiratory 
complications.[15,36‑38] The overall mortality rate in our 
series (4.8%) was, however, much less than the crude death 
rate of 7% in the Indian population.[39] The most common 
cause of mortality was congestive cardiac failure, a fact that 
correlated with the previous literature.[38] The perioperative 
mortality was 1.5% (4 patients) in our series.
The limitation of our study was the lack of availability of complete 
hormonal profile in all the patients and the use of different assay 
systems over a period of time. The Immulite assay, even after 
recalibration, is 3 times higher than the Nichols assay and 6 times 
higher than the Diagnostic System Laboratories assay. Therefore, 
it might have underestimated the cure rate.[40] The other limitation 
was the non‑availability of comparative GH values between the 
Immulite and Cobas e602 assays. The future will be of molecular 
biology and system biology to diagnose the disease at an early 
stage and predict the response to pharmacotherapy.[41,42]
Conclusions
Acromegaly is a disabling disease, but often curable. Our patients 
presented with an advanced and aggressive disease, and a higher 
GH level. The majority of them harbored a macroadenoma and had 
lower cure rates. The critical factor in achieving the desired results 
was the early diagnosis and treatment by a multi‑disciplinary 
team dedicated to the management of pituitary disorders and 
performance of surgery by a dedicated neurosugeon. Moreover, 
a microadenoma is associated with lesser complications and 
a higher cure rate compared to larger tumors. In a resource 
constrained nation like ours, it would be cost effective to develop 
a dedicated surgical team focused on management of pituitary 
disorders, as administration of a prolonged medical therapy in 
the event of treatment failure is often unaffordable.
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